Efficacy and Safety of Once-Weekly Insulin Icodec vs. Once-Daily Basal Insulin in Individuals with Type 2 Diabetes by Kidney Function—ONWARDS 1–5

Introduction & objective: This post hoc analysis assessed the efficacy and safety of once-weekly insulin icodec (icodec) vs once-daily (OD) basal insulin in insulin-naive (ONWARDS 1, 3, 5) and insulin-experienced (ONWARDS 2, 4) adults with T2D by kidney function subgroup.

Methods: Treatment outcomes were analyzed by kidney function subgroup (eGFR≥90; eGFR≥60 -<90; eGFR≥30-<60; eGFR<30; all mL/min/1.73m2).

Results: In ONWARDS 1, 3, and 5, there were no statistically significant treatment by kidney function subgroup interactions for change in A1C from baseline to planned end of treatment (EOT); however, in ONWARDS 2 and 4, there were significant subgroup interactions with higher A1c in the icodec group in patients with mild renal impairment, but not for normal kidney function or moderate renal impairment. No trend for heterogeneity was observed by kidney function sub-group for overall rates of clinically significant or severe hypoglycemia. Across kidney function subgroups, the proportion of participants achieving A1C<7% without clinically significant or severe hypoglycemic episodes at EOT was similar or higher for icodec vs comparators. Additionally, there were no statistically significant differences in average weekly insulin doses for icodec vs OD comparators by kidney function subgroup during the last 2 weeks of treatment in ONWARDS 1-5.

Conclusion: Overall, the efficacy and safety for once-weekly icodec vs OD comparators was consistent, with no trend across kidney function subgroups.

Publikationsverlauf

Artikel online veröffentlicht:
28. Mai 2025